US4797277A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Method for reperfusion therapy
Assignee: Pfizer Health AB
•
Filing: 1987-09-22
•
Granted: 1989-01-10
•
Expires: 2007-09-22
Abstract
Abstract Method for reperfusion therapy of a mammalian organ comprising the step of administering systemically to said organ a therapeutically active amount of an antibody preparation having specificity for a LAC-epitope that is responsible for leukocyte-endothelial cell adherence.
Inventors
- 👤 Karl E. Arfors
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-10-24 03:32
CPC Classifications
C; C07; C07K; C07K16/00; C07K16/18; C07K16/28; C07K16/2839; C07K16/2845; A; A61; A61K; A61K38/00
Claims Analysis
Total Claims: 8
Claim 1
Independent Claim
37 words
Method for reperfusion therapy of a mammalian organ comprising the step of administering systemically to said organ a therapeutically active amount of an antibody preparation having specificity for a LAC-epitope that is responsible for leukocyte-endothelial cell adherence.
Claim 2
Dependent Claim
37 words
Method for reperfusion therapy of a mammalian organ comprising the step of administering systemically to said organ a therapeutically active amount of an antibody preparation having specificity for a LAC-epitope that is responsible for leukocyte-endothelial cell adherence.
Claim 3
Dependent Claim
11 words
The method of claim 1, wherein the antibody preparation is monoclonal.
Claim 4
Dependent Claim
16 words
The method of claim 2, wherein 0.01-5 mg antibody giving the preparation its specificity is administered.
Claim 5
Dependent Claim
17 words
The method of claim 1, wherein said antibody preparation is substantially free from antibodies having other specificities.
Claim 6
Dependent Claim
16 words
The method of claim 4, wherein said antibody comprises modified antibodies, fragmented antibodies, and synthetic compounds.
Claim 7
Dependent Claim
21 words
The method of claim 1, wherein said antibody preparation is selected from the group consisting of polyclonal antibodies and monoclonal antibodies.
Claim 8
Dependent Claim
21 words
The method of claim 1, wherein said antibody preparation is selected from the group consisting of MoAb 60.3, IB4, and CL54.
References Cited (Backward Citations)
No citation records indexed.
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1992-01-10 | 1992-07-11 | 1993-01-10 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1996-01-10 | 1996-07-11 | 1997-01-10 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 2000-01-10 | 2000-07-11 | 2001-01-10 | $7700.00 | Window Closed / Lapsed |